Van ECK Associates Corp cut its stake in Repligen Co. (NASDAQ:RGEN – Free Report) by 2.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,552 shares of the biotechnology company’s stock after selling 1,611 shares during the period. Van ECK Associates Corp owned about 0.10% of Repligen worth $8,675,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Oppenheimer Asset Management Inc. lifted its position in Repligen by 327.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 16,254 shares of the biotechnology company’s stock valued at $2,299,000 after acquiring an additional 12,453 shares during the last quarter. Atria Investments Inc purchased a new stake in shares of Repligen in the third quarter valued at about $1,046,000. Portside Wealth Group LLC purchased a new stake in shares of Repligen in the second quarter valued at about $4,008,000. Fortis Capital Management LLC purchased a new stake in shares of Repligen in the third quarter valued at about $1,479,000. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in shares of Repligen by 130.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 11,500 shares of the biotechnology company’s stock valued at $1,829,000 after buying an additional 6,500 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.
Repligen Trading Up 0.5 %
Shares of RGEN opened at $205.00 on Friday. The firm’s 50-day moving average is $179.97 and its two-hundred day moving average is $165.76. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $208.16. The firm has a market capitalization of $11.45 billion, a P/E ratio of 100.99, a PEG ratio of 4.75 and a beta of 1.04.
Wall Street Analyst Weigh In
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Five stocks we like better than Repligen
- How to Invest in Apparel Stocks
- Cloudflare results spark analysts reset: 25% upside ahead
- Why is the Ex-Dividend Date Significant to Investors?
- Beyond Nvidia: The hidden stars with 200% earnings growth
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 large caps with RSIs that scream ‘oversold’
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.